Personalized neck radiation for nasopharyngeal cancer patients
Individualized Elective Neck Irradiation Based on the Lymph Node Metastasis Pattern in NPC Patients
This study is testing if personalized neck radiation for nasopharyngeal cancer patients can reduce side effects and improve quality of life while still keeping survival rates high.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Enrollment | 470 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Sun Yat-sen University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Guangzhou, Guangdong) |
| Trial ID | NCT06241612 on ClinicalTrials.gov |
What this trial studies
This phase 3 trial evaluates the effectiveness of individualized elective neck irradiation for patients with nasopharyngeal carcinoma (NPC) based on the vertebral level of metastatic lymph nodes. The study aims to determine if this tailored approach can reduce radiation-related side effects and enhance patients' quality of life while maintaining survival rates. By utilizing advanced imaging techniques like MRI and PET-CT, the trial seeks to accurately assess lymph node involvement and optimize treatment. The hypothesis is that targeted irradiation will lead to fewer adverse effects compared to standard whole-neck irradiation.
Who should consider this trial
Good fit: Ideal candidates include newly diagnosed, untreated NPC patients aged 18 to 70 with specific staging and adequate health parameters.
Not a fit: Patients with previous treatments for NPC or other malignancies, or those with severe coexisting illnesses, may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of life for NPC patients by minimizing radiation side effects.
How similar studies have performed: Previous studies have shown success with similar individualized approaches in radiation therapy, indicating potential for this method.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * The eligibility criteria are: newly diagnosed, untreated, non-distant metastatic, and non-keratinizing NPC; nodes are diagnosed with PET/CT and MRI; staged as T1-4N0-2 or N3 category of non-bilateral lower-neck node metastasis; aged between 18 and 70 years; Karnofsky performance-status score \> 70; adequate haematological function, with a leucocyte count \> 4 × 109/L, haemoglobin \> 90 g/L, and a thrombocyte count \> 100×109/L Exclusion Criteria: * The exclusion criteria include: previous chemotherapy treatment, surgery (except diagnostic) or radiotherapy to the neck or nasopharyngeal regions; previous malignancy; lactation or pregnancy; or severe coexisting illness.
Where this trial is running
Guangzhou, Guangdong
- Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China (Recruiting)
Study contacts
- Study coordinator: Ling-Long Tang, Prof
- Email: tangll@sysucc.org.cn
- Phone: 02087343840
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.